FDA Determines Regulatory Review Period for APTIVUS Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for APTIVUS, a human drug product, in accordance with federal regulations. This decision was prompted by a patent extension application submitted to the US Department of Commerce.